Company
Crinetics
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
1
Originals and new uses
Phase 3 trials
5
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Palsonify approved NovelOrphanSep 25, 2025
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)Pivotal-lookingRecruiting
Crinetics Pharmaceuticals Inc.Industry
NCT07159841 · 153 participants (planned) · Start Jan 22, 2026 · Primary completion Mar 2030
Drug: Atumelnant; Placebo · For: Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
Sites: Los Angeles, California; San Francisco, California; Chicago, Illinois · 53 sites in all
- A Study to Evaluate Atumelnant in Adults With Congenital Adrenal HyperplasiaPivotal-lookingRecruiting
Crinetics Pharmaceuticals Inc.Industry
NCT07144163 · 150 participants (planned) · Start Dec 11, 2025 · Primary completion May 2027
Drug: Atumelnant; Placebo · For: Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia
Sites: Los Angeles, California; Aurora, Colorado; Gainesville, Florida · 82 sites in all
Marketed drugs (1)
Newest FDA action first.
- Palsonify Paltusotine Hydrochloride · 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.